Table 1.

Analysis of various clinical and biological characteristics at the beginning and during treatment to predict for a sustained CCgR

VariableAll patientsPatients who lost CCgR (n)P
Sex0.13
    Female4112
    Male567
Age (y)1.00
    ≤658216
    >65153
Disease history0.96
    Intolerant to IFN203
    Hematologic resistance to IFN326
    Cytogenetic resistance to IFN458
Time from diagnosis to start of imatinib (mo)1.00
    ≤24122
    >248517
Time to CCgR (mo)0.29
    ≤66811
    >6298
Log reduction at the time of CCgR0.006
    ≥3 log371
    <3 log6018
BCR-ABL/β2 microglobulin ratio % at the time of CCgR0.01
    ≤0.0005392
    >0.00055817